Harpoon Therapeutics, Inc. (NASDAQ:HARP – Get Rating) has been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $4.71.
Several equities analysts have recently commented on HARP shares. Canaccord Genuity Group lowered their price objective on Harpoon Therapeutics from $16.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, April 3rd. HC Wainwright lowered their price target on Harpoon Therapeutics from $7.00 to $4.50 and set a “buy” rating on the stock in a report on Wednesday, March 29th. Finally, 500.com restated a “reiterates” rating on shares of Harpoon Therapeutics in a research note on Monday, May 15th.
Insider Buying and Selling at Harpoon Therapeutics
In other Harpoon Therapeutics news, Director Ronald Hunt bought 10,000 shares of the business’s stock in a transaction that occurred on Thursday, March 23rd. The stock was purchased at an average cost of $1,000.00 per share, with a total value of $10,000,000.00. Following the completion of the acquisition, the director now owns 10,000 shares in the company, valued at approximately $10,000,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 13.00% of the stock is currently owned by company insiders.
Institutional Trading of Harpoon Therapeutics
Harpoon Therapeutics Trading Up 1.8 %
Harpoon Therapeutics stock opened at $0.76 on Friday. Harpoon Therapeutics has a 12-month low of $0.54 and a 12-month high of $3.35. The firm has a market capitalization of $24.52 million, a price-to-earnings ratio of -0.44 and a beta of 1.56. The firm has a 50 day moving average of $0.68 and a 200 day moving average of $0.77.
Harpoon Therapeutics (NASDAQ:HARP – Get Rating) last posted its quarterly earnings results on Monday, March 27th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.08). Harpoon Therapeutics had a negative return on equity of 473.13% and a negative net margin of 169.83%. The firm had revenue of $4.09 million during the quarter, compared to the consensus estimate of $11.06 million. On average, analysts predict that Harpoon Therapeutics will post -1.13 EPS for the current year.
Harpoon Therapeutics Company Profile
Harpoon Therapeutics, Inc is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies.
- Get a free copy of the StockNews.com research report on Harpoon Therapeutics (HARP)
- monday.com Surges on Price and Volume after Blowout Results
- Can Ryanair Stock Fly Above Resistance Levels, What Earnings Show
- All Aboard! The Sell-Side Has Railroads In Reversal
- Is There Value Left in Lyft Stock?
- Everything About ZIM Integrated Screams Undervaluation
Receive News & Ratings for Harpoon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harpoon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.